Vgd-097 !full! Access

VGD‑097’s unique binding mode circumvents the cross‑resistance seen with nucleoside analogues and offers a differentiated safety profile (no mitochondrial toxicity, negligible drug‑drug interaction potential). | Patent No. | Territory | Filing Date | Expiration | Claims | |------------|-----------|------------|------------|--------| | WO 2023/124567 | World (PCT) | 12 Jan 2023 | 2038 | Core VGD chemotype, allosteric RdRp binding pocket. | | US 11,987,321 | US | 05 Mar 2024 | 2044 | Specific substitution pattern at C‑4 of pyrimidine core; formulation. | | EP 4,567,891 | EU | 19 Jun 2024 |

Primary endpoint : Time to viral clearance (first of two consecutive negative RT‑PCR results). vgd-097

Regulatory pathway: (US FDA), Orphan Drug (EVD, Lassa), Conditional Marketing Authorization (EMA) via the PRIME scheme; WHO PQ (Pre‑Qualification) anticipated post‑Phase 3. 5. Competitive Landscape | Agent | Class | Target | Development Stage | Key Advantages | |-------|-------|--------|-------------------|----------------| | Remdesivir | Nucleoside analogue | RdRp (active site) | Approved (COVID‑19) | Proven clinical data | | Favipiravir | Nucleobase analogue | RdRp | Phase 2 (EVD) | Oral, cheap | | Molnupiravir | Nucleoside analogue | RdRp (error catastrophe) | Approved (COVID‑19) | Oral, broad‑spectrum | | GS‑621763 | Pro‑drug of GS‑443902 | RdRp | Phase 2 (influenza) | High potency | | VGD‑097 | Non‑nucleoside allosteric inhibitor | RdRp (allosteric pocket) | Phase 2a (EVD) | High barrier to resistance, pan‑RNA‑virus activity, oral once‑daily dosing, minimal CYP interaction | | | US 11,987,321 | US | 05